{"cik":1129928,"taxonomy":"us-gaap","tag":"AllocatedShareBasedCompensationExpense","label":"Share-based Payment Arrangement, Expense","description":"Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.","entityName":"ONCOLYTICS BIOTECH INC.","units":{"USD":[{"start":"2024-01-01","end":"2024-12-31","val":1982000,"accn":"0001129928-26-000020","fy":2025,"fp":"FY","form":"10-K","filed":"2026-03-30","frame":"CY2024"},{"start":"2025-01-01","end":"2025-03-31","val":845000,"accn":"0001129928-26-000033","fy":2026,"fp":"Q1","form":"10-Q","filed":"2026-05-14","frame":"CY2025Q1"},{"start":"2025-01-01","end":"2025-06-30","val":1207000,"accn":"0001129928-26-000051","fy":2026,"fp":"Q2","form":"10-Q","filed":"2026-08-12"},{"start":"2025-04-01","end":"2025-06-30","val":362000,"accn":"0001129928-26-000051","fy":2026,"fp":"Q2","form":"10-Q","filed":"2026-08-12","frame":"CY2025Q2"},{"start":"2025-01-01","end":"2025-12-31","val":6571000,"accn":"0001129928-26-000020","fy":2025,"fp":"FY","form":"10-K","filed":"2026-03-30","frame":"CY2025"},{"start":"2026-01-01","end":"2026-03-31","val":3029000,"accn":"0001129928-26-000033","fy":2026,"fp":"Q1","form":"10-Q","filed":"2026-05-14","frame":"CY2026Q1"},{"start":"2026-01-01","end":"2026-06-30","val":5474000,"accn":"0001129928-26-000051","fy":2026,"fp":"Q2","form":"10-Q","filed":"2026-08-12"},{"start":"2026-04-01","end":"2026-06-30","val":2445000,"accn":"0001129928-26-000051","fy":2026,"fp":"Q2","form":"10-Q","filed":"2026-08-12","frame":"CY2026Q2"}]}}